Application of autologous hemopoietic stem cells in inoperable patients with chronic critical lower limb ischemia

The OBJECTIVE was to study the efficiency of transplantation of autologous hematopoietic stem cells in patients with chronic critical lower limb ischemia and compare the results of treatment depending on the number of their transplantations.
METHODS AND MATERIALS. 9 patients with chronic critical lower limb ischemia, recognized as inoperable, received courses of conservative therapy in clinic supplemented with transplantation of autologous hematopoietic stem cells. Patients were divided into 2 groups. The first group included 4 patients who underwent from 2 to 6 transplantations of autologous hematopoietic stem cells at six-month intervals. The second group included 5 patients who underwent only 1 transplantation of autologous hematopoietic stem cells. The effectiveness of treatment was evaluated by objective and subjective signs: an increase in the distance of painless walking, an increase in the ankle-shoulder index. Microcirculation was assessed using three-phase scintigraphy.
RESULTS. Relief of rest pains was noted in all patients. The distance of pain-free walking ranged from 200 to 600 m, the ankle-brachial index increased in 8 out of 9 patients. Scintigraphy data demonstrated the improvement of microcirculation in all patients.
CONCLUSION. The use of autologous hematopoietic stem cells is an effective method in treatment of chronic critical lower limb ischemia. The number of transplantations of autologous hematopoietic stem cells does not affect the clinical effect. Further research is needed in the field of cell therapy for chronic critical lower limb ischemia.

1. Pokrovskiy A. V., Kazakov Yu. I., Lukin I. B. Kriticheskaya ishemiya nizhnikh konechnostey: infraingvinal’noe porazhenie. Tver’, 2018:225. (In Russ.)

2. Chervyakov Yu. V., Vlasenko O. N., Kha Kh. N. Five-year conservative therapy results in patients with lower extremity arterial atherosclerosis at critical ischemia stage // Perm Medical Journal. 2017;34(5):20–27. (In Russ.).

3. Zubova E. S., Vavilov V. N., Artyushin B. S., Movchan K. N., Krutikov A. N., Romanenkov N. S., Iskhakov R. B. Possibilities of the application of hemopoetic cells of monocytary series in thetreatment of patients with critical limb ischemia // Modern problems of science and education. 2019;(3). (In Russ.). Available at: https://science-education.ru/ru/article/view?id=28990 (accessed: 20.11.2021).

4. Kret M. R., Perrone K. H., Azarbal A. F., Mitchell E. L., Liem T. K., Landry G. J., Moneta G. L. Medical comorbidities but not interventions adversely affect survival in patients with intermittent Claudication // J Vasc Surg. 2013;58(6):1540–1546. Doi:10.1016/j.jvs.2013.07.012.

5. Conte M. S., Bradbury A. W., Kolh P., White J. V., Dick F., Fitridge R. et al. Global vascular guidelines on the management of chronic limbthreatening ischemia // Eur J Vasc Endovasc Surg. 2019;58(1S):S1– S109.e33. Doi:10.1016/j.ejvs.2019.05.006. PMID:31182334.

6. Lebedev S. V., Karasev A. V., Kungurtsev V. V., Lokhonina A. V., Kleymenova E. B. Cell therapy of critical limb ischemia (problems and prospects) // Annals of the Russian academy of medical sciences. 2013;68(3):33–44. (In Russ.).

7. Sukovatykh B. S., Orlova A. Yu. Stimulyatsiya angiogeneza kletkami kostnogo mozga pri eksperimental’noy ishemii konechnosti // Angiology and Vascular Surgery. 2017; 23(1):43–50. (In Russ.).

8. Kaputin M. Yu., Burnos S. N. Primenenie stvolovykh kletok dlya lecheniya bol’nykh skriticheskoy ishemiey nizhnikh konechnostey // Grekov’s Bulletin of Surgery. 2015;174(1):103–108. (In Russ.).

9. Peeters Weem S. M., Teraa M., de Borst G. J., Verhaar M. C., Moll F. L. Bone marrow derived cell therapy in critical limb ischemia: a metaanalysis of randomized placebo controlled trials // Eur J Vasc Endovasc Surg. 2015;50(6):775–783. Doi:10.1016/j.ejvs.2015.08.018.

10. Losordo D. W., Kibbe M. R., Mendelsohn F., Marston W., Driver V. R., Sharafuddin M. et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia // Circ Cardiovasc Interv. 2012;5:821–830.

11. Powell R. J., Marston W. A., Berceli S. A., Guzman R., Henry T. D., Longcore A. T. et al. Cellular therapy with Ixmyelocel-T to treatcritical limb ischemia: therandomized, double-blind, placebo-controlled RESTORECLI trial // MolTher. 2012;20:1280–1286.

12. Rutherford R. B., Baker J. D., Ernst C., Johnston K. W., Porter J. M., Ahn S., Jones D. N. Recommended standards for reports dealing with lower extremity ischemia: revised version // J Vasc Surg. 1997;26(3):517–538. Doi:10.1016/s0741-5214(97)70045-4.